How do I know if my Bladder Cancer has an actionable mutation

Understanding Actionable Mutations in Bladder Cancer

Great question—this is one of the most important things to understand about your cancer care. Let me explain what "actionable" means and how doctors determine if your bladder cancer has one.

What Is an "Actionable" Mutation?

An actionable mutation is a genetic change in your cancer cells that doctors can target with a specific, FDA-approved treatment. Think of it like a lock-and-key system: if your cancer has a particular mutation (the lock), there's a drug designed to fit that mutation (the key).

Key Actionable Mutations in Bladder Cancer

According to the NCCN Guidelines for Bladder Cancer (2025), the most important mutations to test for are:

FGFR3 Alterations

• What it means: Your cancer cells have changes in a gene called FGFR3
• Why it matters: If present, you may be eligible for erdafitinib, an FDA-approved targeted therapy specifically designed for FGFR3 mutations
• Who should be tested: All patients with advanced (unresectable or metastatic) bladder cancer

HER2 Overexpression

• What it means: Your cancer cells produce too much of a protein called HER2
• Why it matters: If HER2 is overexpressed, you may be eligible for fam-trastuzumab deruxtecan (Enhertu), an FDA-approved targeted therapy
• Testing method: Immunohistochemistry (IHC) testing on your tumor tissue

Microsatellite Instability (MSI-H) or Mismatch Repair (MMR) Deficiency

• What it means: Your cancer cells have problems with their DNA repair systems
• Why it matters: This may make your cancer responsive to checkpoint inhibitor immunotherapy drugs
• Clinical significance: According to NCCN Guidelines, this status should be evaluated for all patients with advanced bladder cancer

When Should You Get Tested?

According to NCCN Guidelines, molecular/genomic testing is recommended for:

✅ Definitely test if you have:

• Stage IVA or IVB (metastatic/advanced) bladder cancer
• Unresectable bladder cancer

✅ May consider testing if you have:

• Stage IIIB disease

⚠️ Important note: For muscle-invasive bladder cancer (MIBC) that is resectable, routine somatic tumor testing is NOT routinely recommended unless it enables you to participate in a clinical trial.

How the Testing Works

Your doctor will order comprehensive genomic profiling (also called a "tumor panel") performed in a CLIA-certified laboratory. This means:

• A sample of your tumor tissue is analyzed
• The lab looks for multiple genetic mutations at once
• Results typically take 1-2 weeks
• The report will tell you which mutations are present and which treatments they may qualify you for

What the Results Mean for Your Treatment

According to NCCN Guidelines, if you have actionable mutations:

| Mutation Found | Potential Treatment | Next Step | |---|---|---| | FGFR3 alteration | Erdafitinib (targeted therapy) | Discuss with your oncologist | | HER2 overexpression | Fam-trastuzumab deruxtecan | Discuss with your oncologist | | MSI-H/MMR deficiency | Checkpoint inhibitors | Discuss with your oncologist |

Important Questions to Ask Your Oncologist

1. "Has my tumor been tested for FGFR3, HER2, and MSI-H/MMR status?" If not, ask why and whether testing is recommended for your stage.

2. "What mutations did my tumor have, and what do they mean for my treatment options?"

3. "Are there any FDA-approved targeted therapies I'm eligible for based on my results?"

4. "Are there clinical trials available for my specific mutation?"

5. "If I don't have actionable mutations, what are my other treatment options?"

6. "Can I get a copy of my full genomic testing report to share with other doctors if I want a second opinion?"

A Critical Caveat

The NCCN Guidelines emphasize that circulating tumor DNA (ctDNA) testing—blood tests that look for cancer DNA—currently has insufficient evidence to guide treatment decisions or surveillance after surgery. So if your doctor mentions ctDNA results, understand that these are still being studied and shouldn't be the only factor in treatment decisions.

Bottom Line

You have an actionable mutation if your tumor has FGFR3, HER2, or MSI-H/MMR changes AND you have advanced bladder cancer. The only way to know for sure is through comprehensive genomic testing ordered by your oncologist. Make sure this testing happens early in your diagnosis so you don't miss out on targeted treatment options.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.